… Both NHLBAC working groups facilitated our evaluation of the existing landscape and … , to
assume the governance and management of these prevention guidelines and to ensure their …

… prevention by mechanisms that increase the hepatic clearance of apolipoprotein B-containing
lipoproteins … Bempedoic acid is currently evaluated in the CLEAR Outcomes trial of statin-…

… This study was the first primary prevention study to show that individuals with HDL-C <40
mg/dL … This study evaluated the effect of exogenous administration of ETC-216 on coronary …

… Very low-density lipoproteins are subsequently converted into … the lipoprotein profile and
may potentially be a new strategy for reducing CVD. Large-scale, randomized trials evaluating …

… prevention are sparse and new lipid-modifying therapies that reduce Lp(a) are in development
(12–15), we assessed the independent prognostic utility of Lp(a) and evaluated proposed …

… Statin therapy has become the most important advance in stroke prevention since the
introduction of aspirin and blood pressure-lowering therapies. In combination with other preventive …

Elevated levels of low-density lipoprotein cholesterol (LDL-C) are associated with increased
risk of coronary heart disease and stroke. Guidelines for the management of dyslipidaemia …

… prevention was <100 mg/dL, the NCQA set its new HEDIS performance metric as the percentage
of secondary prevention … dL) versus a performance measure for evaluating the care of a …

… In this review, we evaluate the causal role of Lp(a) across the cardiovascular disease spectrum,
examine the role of established lipid-modifying therapies in lowering Lp(a), and focus on …

… ACCF/AHA 2007 clinical expert consensus document on coronary artery calcium scoring
by computed tomography in global cardiovascular risk assessment and in evaluation of …